Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus CYCLOCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus CYCLOCORT.
CAPEX vs CYCLOCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production, inhibits phospholipase A2, and reduces prostaglandin synthesis.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
Apply a thin film topically to affected area twice daily (morning and evening). Not for ophthalmic use.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
3.5 hours (terminal); clinical effect duration longer due to tissue binding.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Primarily hepatic metabolism; inactive metabolites excreted renally (<1% unchanged) and in feces (biliary).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid